The long-term efficacy and safety of new biological therapies for psoriasis

Archives of Dermatological Research

Volumn 298, Issue 1, 2006, Pages 7-15

  Papp, Kim A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Alefacept; Biological; Efalizumab; Etanercept; Infliximab; Long term treatment; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; RETINOID;

CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; INFLUENZA; INJECTION SITE PAIN; LONG TERM CARE; LYMPHOMA; MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; RHINOPHARYNGITIS; SHORT SURVEY; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646589648     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-006-0660-6     Document Type: Short Survey

References (29)

1. Carey W, Glazer S, Gottlieb AB et al (2006) Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54(4 suppl 1):S171-S181
2. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271):1842-1847
3. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248-255
4. Gollnick HP (1996) Oral retinoids - efficacy and toxicity in psoriasis. Br J Dermatol 125 (suppl 49):6-17
5. Gollnick HP, Dummler U (1997) Retinoids. Clin Dermatol 15:799-810
6. Gordon KB, Papp KA, Hamilton TK et al (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073-3080
7. Gottlieb AB, Gordon KB, Lebwohl MG et al (2004) Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 3:614-624
8. Gottlieb AB, Evans R, Li S et al (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534-542
9. Gottlieb AB, Hamilton T, Caro I et al (2006) Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54(4 suppl 1):S154-S163
10. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC (2000) A systematic review of treatments for severe psoriasis. Health Technol Assess 4:1-125
11. Griffiths CE, Dubertret L, Ellis CN et al (2004) Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 150(suppl 67):11-23
12. Honigsmann H (2001) Phototherapy for psoriasis. Clin Exp Dermatol 26:343-350
13. Jullien D, Prinz JC, Langley RGB et al (2004) T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 208:297-306
14. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821-833
15. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719-727
16. Lebwohl M, Tyring SK, Hamilton TK et al (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004-2013
17. Leonardi CL, Papp KA, Gordon KB et al (2005) Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52(3 Pt 1):425-433
18. Leonardi CL, Powers JL, Matheson RT et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022
19. Menter A, Gordon K, Carey W et al (2005) Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141:31-38
20. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr (2004) Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3:27-38
21. Naldi L, Griffiths CE (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597-615
22. Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664-1675
23. Nijsten TE, Stern RS (2003) The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 121:252-258
24. Papp KA, Bressinck R, Fretzin S et al (2005) Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol [Epub ahead of print] Available at: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-4632.2006.02777.x
25. Papp KA, Tyring S, Lahfa M et al (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304-1312
26. Reich K, Nestle FO, Papp K et al.; EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367-1374
27. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38:478-485
28. Sterry W, Dubertret L, Papp K, Chimenti S, Larsen CG (2004) Efalizumab for patients with moderate to severe chronic plaque psoriasis: results of the international, randomized, controlled phase III clinical experience Raptiva (CLEAR) trial. J Invest Dermatol 123(2):A64
29. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ (2003) Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 49(Suppl 2):S66-S77